ATE226085T1 - Pharmazeutische formulierungen enthaltend nervenwachstumsfaktor - Google Patents

Pharmazeutische formulierungen enthaltend nervenwachstumsfaktor

Info

Publication number
ATE226085T1
ATE226085T1 AT94925903T AT94925903T ATE226085T1 AT E226085 T1 ATE226085 T1 AT E226085T1 AT 94925903 T AT94925903 T AT 94925903T AT 94925903 T AT94925903 T AT 94925903T AT E226085 T1 ATE226085 T1 AT E226085T1
Authority
AT
Austria
Prior art keywords
growth factor
nerve growth
pharmaceutical formulations
formulations containing
containing nerve
Prior art date
Application number
AT94925903T
Other languages
English (en)
Inventor
Victoria M Knepp
Deborah M Lidgate
Richard Maskiewicz
Leo Gu
Original Assignee
Syntex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Llc filed Critical Syntex Llc
Application granted granted Critical
Publication of ATE226085T1 publication Critical patent/ATE226085T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94925903T 1993-08-20 1994-08-16 Pharmazeutische formulierungen enthaltend nervenwachstumsfaktor ATE226085T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/109,798 US6277828B1 (en) 1993-08-20 1993-08-20 Pharmaceutical formulations of nerve growth factor
PCT/US1994/009245 WO1995005845A1 (en) 1993-08-20 1994-08-16 Pharmaceutical formulations of nerve growth factor

Publications (1)

Publication Number Publication Date
ATE226085T1 true ATE226085T1 (de) 2002-11-15

Family

ID=22329623

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925903T ATE226085T1 (de) 1993-08-20 1994-08-16 Pharmazeutische formulierungen enthaltend nervenwachstumsfaktor

Country Status (32)

Country Link
US (2) US6277828B1 (de)
EP (1) EP0721343B1 (de)
JP (2) JP4592830B2 (de)
KR (1) KR100341193B1 (de)
CN (1) CN1163265C (de)
AT (1) ATE226085T1 (de)
AU (1) AU677699B2 (de)
BG (1) BG62951B1 (de)
BR (1) BR9407278A (de)
CA (1) CA2169834C (de)
CZ (1) CZ292422B6 (de)
DE (1) DE69431562T2 (de)
DK (1) DK0721343T3 (de)
ES (1) ES2181723T3 (de)
FI (1) FI113241B (de)
HK (1) HK1012990A1 (de)
HU (1) HU228152B1 (de)
IL (3) IL124941A (de)
LT (1) LT4051B (de)
LV (1) LV11279B (de)
NO (1) NO317627B1 (de)
NZ (1) NZ271873A (de)
PL (1) PL176387B1 (de)
PT (1) PT721343E (de)
RO (1) RO114742B1 (de)
RU (1) RU2126265C1 (de)
SI (1) SI9420048B (de)
SK (1) SK284064B6 (de)
TW (1) TW427905B (de)
UA (1) UA43348C2 (de)
WO (1) WO1995005845A1 (de)
ZA (1) ZA946333B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
WO1996035446A1 (en) * 1995-05-12 1996-11-14 The Rockefeller University Treatment of alzheimer disease by modulation of synapsins
US6964947B1 (en) 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
US6090781A (en) * 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
IL124004A (en) * 1995-11-07 2003-10-31 Genentech Inc Stable pharmaceutical composition comprising ngf
AU3214597A (en) * 1996-05-29 1998-01-05 Universal Preservation Technologies, Inc. Long-term shelf preservation by vitrification
CN1059597C (zh) * 1996-08-08 2000-12-20 陈素兰 神经损伤修复制剂
PT994721E (pt) * 1997-05-01 2007-03-30 Protechtion Unltd Inc Factor de crescimento do tecido nervoso como adjuvante de vacina
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
CA2304720A1 (en) * 1997-09-30 1999-04-08 Duke University Apolipoprotein e/growth factor complexes and methods of use
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
AU2002351756A1 (en) * 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
PL207018B1 (pl) 2002-06-21 2010-10-29 Novo Nordisk Helth Care Ag Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
EP1605968A2 (de) * 2003-03-18 2005-12-21 Novo Nordisk Health Care AG Flüssige, wässrige, pharmazeutische zusammensetzungen von faktor-vii-polypeptiden
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
KR20060015574A (ko) * 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
WO2004112828A1 (en) * 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
ES2574581T3 (es) * 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
RU2373953C2 (ru) * 2003-12-19 2009-11-27 Ново Нордиск Хелс Кеа Аг Стабилизированная композиция, содержащая полипептид фактора vii
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
EP2052723A4 (de) * 2006-08-14 2010-07-28 Eisai R&D Man Co Ltd Stabile lyophilisierte zubereitung
EP2081645B8 (de) * 2006-11-08 2013-07-10 P· MIND Co., Ltd Gerät zur beschleunigung der produktion von neurotrophem faktor
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
CN102196822A (zh) * 2008-09-26 2011-09-21 阿道恰公司 由多糖和hbp构成的复合物
CN102232932B (zh) * 2010-04-27 2013-06-05 重庆莱美药业股份有限公司 果胶-阿霉素轭合物的冻干制剂及制备方法
US9993565B2 (en) 2011-04-07 2018-06-12 Neovacs Method for treating IFNalpha related conditions
US20150005236A1 (en) * 2012-02-08 2015-01-01 Institut National De La Recherche Agronomique Use of beta-nerve growth factor for inducing ovulation in mammals
US11077193B2 (en) * 2015-04-21 2021-08-03 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and powder injection
DK3287141T3 (da) * 2015-04-21 2021-10-11 Staidson Beijing Biopharmaceuticals Co Ltd Nervevækstfaktorsammensætning og injektionspulver
US10576129B2 (en) * 2015-04-21 2020-03-03 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and powder injection
US9868828B2 (en) * 2015-06-23 2018-01-16 Amolifescience Co., Ltd. Defined three-dimensional microenvironment for stem cell
EP3434283A4 (de) 2016-03-25 2019-11-13 Astellas Pharma Inc. Medizinische zusammensetzung mit einem fab'-fragment eines menschlichen anti-ngf-antikörpers gegen peg
SI3463308T1 (sl) * 2016-06-01 2022-04-29 Servier IP UK Limited Formulacije polialkilenoksidne asparaginaze in postopki za pripravo in uporabo le-teh
CN109260147B (zh) * 2018-10-15 2019-09-13 珠海亿胜生物制药有限公司 一种用于治疗或预防神经损伤的重组人碱性成纤维细胞生长因子注射剂
US11767504B2 (en) 2020-08-14 2023-09-26 Albcura Corporation Albumin compositions and methods of producing and using same
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222413A (en) 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0418031A (ja) * 1989-02-16 1992-01-22 Hiroshi Saito 損傷治癒促進剤
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JP2818834B2 (ja) * 1991-08-12 1998-10-30 大塚製薬株式会社 ＩＬ−１α安定化医薬製剤

Also Published As

Publication number Publication date
BR9407278A (pt) 1996-10-01
BG100371A (bg) 1996-12-31
IL110725A (en) 2004-09-27
LV11279B (en) 1996-10-20
NO960651D0 (no) 1996-02-19
KR100341193B1 (ko) 2002-06-21
NO317627B1 (no) 2004-11-29
SI9420048B (sl) 2003-12-31
DE69431562D1 (de) 2002-11-21
RU2126265C1 (ru) 1999-02-20
CN1133012A (zh) 1996-10-09
EP0721343B1 (de) 2002-10-16
DK0721343T3 (da) 2003-02-17
FI960750A0 (fi) 1996-02-19
NO960651L (no) 1996-02-19
LV11279A (lv) 1996-06-20
LT4051B (en) 1996-10-25
HK1012990A1 (en) 1999-08-13
US7074763B2 (en) 2006-07-11
JP4592830B2 (ja) 2010-12-08
IL110725A0 (en) 1994-11-11
SI9420048A (en) 1996-10-31
IL124941A0 (en) 1999-01-26
FI113241B (fi) 2004-03-31
US6277828B1 (en) 2001-08-21
RO114742B1 (ro) 1999-07-30
BG62951B1 (bg) 2000-12-29
CZ292422B6 (cs) 2003-09-17
WO1995005845A1 (en) 1995-03-02
ES2181723T3 (es) 2003-03-01
SK284064B6 (sk) 2004-09-08
IL124941A (en) 2006-12-10
CN1163265C (zh) 2004-08-25
HUT74728A (en) 1997-02-28
TW427905B (en) 2001-04-01
EP0721343A1 (de) 1996-07-17
AU677699B2 (en) 1997-05-01
CA2169834C (en) 2008-11-04
AU7566894A (en) 1995-03-21
HU9600371D0 (en) 1996-04-29
NZ271873A (en) 1996-10-28
UA43348C2 (uk) 2001-12-17
PL176387B1 (pl) 1999-05-31
FI960750A (fi) 1996-02-20
CZ42496A3 (en) 1996-05-15
DE69431562T2 (de) 2003-06-18
ZA946333B (en) 1996-02-19
JP2007314572A (ja) 2007-12-06
LT96011A (en) 1996-07-25
PL313084A1 (en) 1996-05-27
SK18396A3 (en) 1996-10-02
HU228152B1 (en) 2012-12-28
US20010007662A1 (en) 2001-07-12
JPH10508000A (ja) 1998-08-04
CA2169834A1 (en) 1995-03-02
PT721343E (pt) 2003-01-31

Similar Documents

Publication Publication Date Title
ATE226085T1 (de) Pharmazeutische formulierungen enthaltend nervenwachstumsfaktor
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
MX9203439A (es) Una citocina mamifera, il-11
FI875533A (fi) Insulinpreparat foer non-parenteral dosering.
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
ATE140483T1 (de) Natürlicher killerzellen-stimulationsfaktor
IT1196484B (it) Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
NO862095L (no) Farmasoeytiske preparater inneholdende vevsplasmnogenaktivitator og fremgangsmaate for deres fremstilling.
ATE225168T1 (de) Verwendung von lycopen zur verminderung der zellaktivität, insbesondere von krebszellen, sowie entsprechende pharmazeutische zubereitungen
BR9611571A (pt) Composição farmacêutica estável composição farmacêutica kit para administração de ngf e método de aumento da estabilidade de ngf
EE03224B1 (et) Prolongeeritud toimega süstesuspensioonid ja nende valmistamismeetod
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
ZA886903B (en) Stabilisation of therapeutically active proteins in pharmaceutical preparations
DE3777411D1 (de) Mittel zur verbesserung der perkutanen verabreichung von arzneimitteln.
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
IT8921516A0 (it) Procedimento di microincapsulazione di microorganismi vivi e composizioni farmaceutiche stabili.
DK326985D0 (da) Farmaceutiske og kosmetiske praeparater indeholdende et anthracenderivat som aktiv bestanddel
ITPS920005A0 (it) Procedimento di costruzione di pannelli in tamburato per mobili in genere, con cornici e scanalature fresate in profondita'
IT1246195B (it) Composizioni farmaceutiche contenenti antibiotici aminoglicosidici atte alla somministrazione topica